EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development

Jeffrey L Cummings iD, Amanda M Leisgang Osse, Jefferson W Kinney, Davis Cammann, Jingchun Chen

CNS Drugs · 2024-08 · 38 (8) · 613-624

DOI: 10.1007/s40263-024-01103-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 27.06.2024. Verfasst von Jeffrey L Cummings und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Ve…. Hauptthemen laut MEDLINE: Alzheimer Disease, Clinical Trials as Topic, Drug Therapy, Combination, Drug Development. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a complex multifaceted disease. Recently approved anti-amyloid monoclonal antibodies slow disease progression by approximately 30%, and combination therapy appears necessary to prevent the onset of AD or produce greater slowing of cognitive and functional decline. Combination therapies may address core features, non-specific co-pathology commonly occurring in patients with AD (e.g., inflammation), or non-AD pathologies that may co-occur with AD (e.g., α-synuclein). Combination therapies may be advanced through co-development of more than one new molecular entity or through add-on strategies including an approved agent plus a new molecular entity. Addressing add-on combination therapy is currently urgent since patients on anti-amyloid monoclonal antibodies may be included in clinical trials for experimental agents. Phase 1 information must be generated for each agent in combination drug development. Phase 2 and Phase 3 of add-on therapies may contrast the new molecular entity, the approved agent as standard of care, and the combination. More complex development programs including standard or modified combinatorial designs are required for co-development of two or more new molecular entities. Biomarkers are markedly affected by anti-amyloid monoclonal antibodies, and these effects must be anticipated in add-on trials. Examining target engagement biomarkers and comparing the magnitude and sequence of biomarker changes in those receiving more than one therapy, compared with those on monotherapy, may be informative. Using network-based medicine approaches, computational strategies may identify rational combinations using disease and drug effect network mapping.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseClinical Trials as TopicDrug Therapy, CombinationDrug DevelopmentHumansAntibodies, MonoclonalAnimals

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV, Las Vegas, NV, USA. jcummings@cnsinnovations.com.
  • Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA. jcummings@cnsinnovations.com.
  • , 1380 Opal Valley Street, Henderson, NV, 89052, USA. jcummings@cnsinnovations.com.
  • Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV, Las Vegas, NV, USA.
  • Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA.
  • Nevada Institute of Personalized Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA.

ORCID-Profile: Jeffrey L Cummings

Förderung

  • NIA NIH HHS
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences
  • National Institute on Aging
  • Alzheimer's Drug Discovery Foundation
  • Ted and Maria Quirk Endowment
  • Joy Chambers-Grundy Endowment

Zitieren

APA

Cummings, J. L., Osse, A. M. L., Kinney, J. W., Cammann, D., & Chen, J. (2024). Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development. CNS Drugs, 38(8), 613-624. https://doi.org/10.1007/s40263-024-01103-1

Vancouver

Cummings JL, Osse AML, Kinney JW, Cammann D, Chen J. Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development. CNS Drugs. 2024;38(8):613-624. doi:10.1007/s40263-024-01103-1

BibTeX
@article{Cummings2024,
  author = {Cummings, Jeffrey L and Osse, Amanda M Leisgang and Kinney, Jefferson W and Cammann, Davis and Chen, Jingchun},
  title = {Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development},
  journal = {CNS Drugs},
  year = {2024},
  volume = {38},
  number = {8},
  pages = {613--624},
  doi = {10.1007/s40263-024-01103-1}
}
Kostenlos starten →